Establishment and verification of miRNAs expression molecules for breast cancer and its distant metastasis Yanhong Gao Associate Professor Department of.

Slides:



Advertisements
Similar presentations
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Advertisements

 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
Prostate cancer: early detection, monitoring and prognosis: Essex Biomedical Sciences Institute (EBSI) Elena Klenova, University of Essex the search for.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
 MicroRNAs (miRNAs) are a class of small RNA molecules, about ~21 nucleotide (nt) long.  MicroRNA are small non coding RNAs (ncRNAs) that regulate.
BIOC 401. Blood Sample To Detect Breast Cancer Cancer is actually a group of many related diseases that all have to do with cells. Cells are the very.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Joakim Dillner, M.D. Professor Department of Laboratory Medicine Karolinska Institutet Sweden Karolinska Institutet.
MammaPrint, the story of the 70-gene profile
Eleni Galani Medical Oncologist
“Discovery Of Gene Ripple Effect Which Causes Cervical Cancer to Advance And Spread” May 19 th, 2011
Fundeni Centre for Immunogenetics & Virology
Mandi Murph1, Tamotsu Tanaka1, Jihai Pang2, Edward Felix2, James Thompson3 and Gordon Mills1 1Department of Systems Biology, 2Department of Experimental.
Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases J.M. Escudero,
Cancer AN INTRODUCTION Cancer - An Introduction 1.
Prostate Cancer By: Kurt Rishel.
DNA MICROARRAYS WHAT ARE THEY? BEFORE WE ANSWER THAT FIRST TAKE 1 MIN TO WRITE DOWN WHAT YOU KNOW ABOUT GENE EXPRESSION THEN SHARE YOUR THOUGHTS IN GROUPS.
Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines.
Tumor markers Present; by Dr. Andalib Isfahan Medical School
Microwave Radiometry Microwave Radiometry. The RTM-01-RES radiometer receives and evaluates the natural electromagnetic radiation (temperature) from the.
BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain.
Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
1 Biochemistry & medicine introduction. 2 1 、 definition  Science concerned with chemical basis of life.
MicroRNA implication in urinary bladder cancer A. Zaravinos 1, J. Radojicic 3, G.I. Lambrou 2, D. Volanis 1,4, D. Delakas 4, E.N. Stathopoulos 3, D.A.
吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Aug 12, 2008
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
Apostolos Zaravinos and Constantinos C Deltas Molecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, Department of Biological.
OncomiR and tumor-suppressor miR expression in triple-negative primary breast cancer. Jelena Radojicic 1, Apostolos Zaravinos 2, Thomas Vrekoussis 1, Maria.
Gene Expression Signatures for Prognosis in NSCLC, Coupled with Signatures of Oncogenic Pathway Deregulation, Provide a Novel Approach for Selection of.
Ranjit Ganta, Raj Acharya, Shruthi Prabhakara Department of Computer Science and Engineering, Penn State University DATA WAREHOUSE FOR BIO-GEO HEALTH CARE.
DIFFERENTIALLY EXPRESSED GENES AND THEIR ASSOCIATED NETWORKS IN CLEAR-CELL RENAL CELL CARCINOMA (RCC) Apostolos Zaravinos and Constantinos C. Deltas Molecular.
Introduction Results Conclusions Acknowledgements Alzheimer’s Disease (AD) is the most common chronic degenerative neurological disease, and there are.
Understanding Cancer and Related Topics
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Biochemical markers for diagnosis of diseases and follow up Dr. Rana Hasanato Associate professor and consultant Head of clinical chemistry department.
Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.
Dr. Jeyaparvathi Somasundaram
NCode TM miRNA Analysis Platform Identifies Differentially Expressed Novel miRNAs in Adenocarcinoma Using Clinical Human Samples Provided By BioServe.
-33 Red bar: tonsil tumour samples, n =14 x2 Green bar: tonsil normal samples, n = 9 x2 A B Supplementary Figure 1. A)Unsupervised HCL analysis was used.
Expression profile of oncomiRs and tumor-suppressor miRs in urothelial carcinoma of the bladder Apostolos Zaravinos 1, George I. Lambrou 2, Jelena Radojicic.
INTRODUCTION & OBJECTIVES Introduction: The carcinogenesis of hepatocellular carcinoma (HCC) is a multifactorial, multistep and complex process. Its prognosis.
Raphael Sandaltzopoulos, PhD, MBA Professor at MBG (Molecular Biology) Lab. of Gene Expression, Molecular Diagnosis and Modern Therapeutics,
Odor-based Sensors for Ovarian Cancer Detection
SURGICAL ONCOLOGY AND TUMOR MARKERS
miRNA-targets cross-talks: key players in glioblastoma multiforme
GENETIC BIOMARKERS.
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
Tel: Serum microRNA-21: a promising diagnostic and prognostic biomarker in Egyptian breast cancer patients.
Circulating microRNAs as novel minimally invasive biomarkers for breast cancer Supplementary Information Helen M. Heneghan1, Nicola Miller1, Aoife J.
Sukhjeet bains Melissa Sylvester Wendy carpio Adriana monterroza
Integrated microRNA-mRNA profiling identifies molecular biomarkers in bladder outlet obstruction-induced lower urinary tract dysfunction Fiona C. Burkhard1,
Table (1):Relation between lymph node and molecular subtypes.
Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma  Jun Wang, MD, PhD, Zhi Li, MD, PhD,
objectives Methods Results conclusion
Potential role of circulating microRNAs as a biomarker for unexplained recurrent spontaneous abortion  Weibing Qin, M.D., Ph.D., Yunge Tang, M.D., Ning.
Altered microRNA expression in stenoses of native arteriovenous fistulas in hemodialysis patients  Lei Lv, MD, Weibin Huang, MD, Jiwei Zhang, MD, Yaxue.
UHRF1 is regulated by miR-9 in colorectal cancer
Transcriptional Signature of Histone Deacetylases in Breast cancer
A microRNA profile comparison between thoracic aortic dissection and normal thoracic aorta indicates the potential role of microRNAs in contributing to.
Effect of Obesity on Prognosis after Early Breast Cancer
Learning More from Microarrays: Insights from Modules and Networks
Introduction To Medical Technology
Volume 23, Issue 8, Pages (August 2015)
Diagnostics and Prognostics
Kun-Peng Zhu, Xiao-Long Ma, Chun-Lin Zhang  Molecular Therapy 
Biochemical markers for diagnosis of diseases and follow up
The Role of TIPE2 Protein in Invasive Breast Carcinoma
Presentation transcript:

Establishment and verification of miRNAs expression molecules for breast cancer and its distant metastasis Yanhong Gao Associate Professor Department of Clinical Biochemistry Chinese PLA General Hospital

 Academy of Medical Sciences, Master degree  Academy of Medical Sciences, Doctor degree  now Department of Clinical biochemistry,Chinese PLA General hospital, Associate Chief physician and Associate Professor  The cancer institute of New Jersey, Rougters University, vistor scholar

My Work  Information and automation management of Clinical Biochemistry ;  Explorating new tumor biomarkers for diagnoses and prognostic from blood by advanced technology methods

PLAGeneralHospital 2015/11/15

PLAGeneralHospital squaremeters 15 floors in the ground 5 floors underground people

PLAGeneralHospital

DepartmentofClinicalBiochemistry 2015/11/15

Departmentof Clinical Biochemistry 1 Biochemistry Laboratory 2 Immunology Laboratory 3 PCR Laboratory 4 Emergency Laboratory Company Logo ery.co m

Biochemical TestItems DiseaseItems number 112 kinds of biochemical items Renal Function4 Pancreatic function2 enough Tumor marker12 Bone metabolism test4 most Nutritional index8 wide Other items6 Molecular biology examination 2 Drug concentration test 3 Blood gas analysis 15 Inorganic ion test 8 Diabetes mellitus 5 Lipid examination 12 Myocardial function 8 Liver Function 12

Technology platform Fully automatic sample processing system Biochemical and Immunology analysis system RSA Pro Cobas /701 、 e602

Emergency automatic sample processing analysis system Combas 221 Emergency Training Combas 8000 FS5600

PCR analysis system COBAS® TaqMan 48 PCR COBAS® AmpliPrep

BiochemicalTestData Every Day : 10,0000 Month : 300,0000 Year : 3600, daymonthyear x 10000

What is big data? How many types of data in medicine ? How to deal with big data?

Establishment and verification of miRNAs expression molecules for breast cancer and its distant metastasis

Breast cancer  Breast cancer is one of malignant tumors in women  Distant metastasis is the main death cause for breast cancer patients  The early detection of laboratory is the key for prevention and therapy breast cancer

 MicroRNAs (miRNAs) are a major class of small endogenous RNA molecules that post-transcriptionally regulate gene expression. Recent researches demonstrated that miRNAs are closely associated with breast cancer the loss of several tumor suppressor miRNAs and the overexpression of certain oncogenic miRNAs have been observed in breast cancers miRNA can be found in the plasma and serum, and it has some advantages over other diseases, and has been shown to be unique in the diagnosis and prognosis of breast cancer, liver cancer, and other diseases.   

 When breast cancer and distant metastasis occur, it may be that themain (is)thethereleaseofendogenousmiRNAsintothethe peripheral blood circulation.  It is very important to explorethe breast cancer and its distant for screening 、 diagnosis cancer. metastasisspecificmiRNAsand prognosis assessment of breast

Methods ( no lymph node GX software calculation of gene expression differences and statistically significant P values Agilent miRNA microarray hybridization groupgroup control mammary gland hyperplasia breast cancer (lymph node metastasis) breast cancer metastasis)

Research Work

Results the normal group was up-regulated, MiRNAs moleculesof whilemiRNAsforgroupB1,B2and B3 were down-regulated. Normal control group (C group): purple; mammary gland hyperplasia group(group B1): red; breast lymph node metastasis (group B2): green; breast lymph node metastasis group (group B3): blue. horizontal coordinates: different colors on behalf of different groups. Vertical coordinates: representing the miRNA molecule. Figure 1. MiRNA Agilent microarray in normal control group, breast hyperplasia group and breast cancer group (yellow shows expressed up, blue shows down regulated).

B1 vs C Result systematisystematip (Corr)pFC (abs)RegulatioRegulatio2_1:gTota2_2:gTota2_3:gTota2_4:gTota2_5:gTota2_6:gTota2_7:gTota2_8:gTota hsa-miR-4hsa-miR up hsa-miR-1hsa-miR-16.39E E down hsa-miR-1hsa-miR-16E-056E E down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR-18.2E-058.2E E down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR-17.56E E down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR-16.22E E down hsa-miR-1hsa-miR-15.87E E down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR-16.44E E down hsa-miR-1hsa-miR-17.43E E down hsa-miR-2hsa-miR down hsa-miR-2hsa-miR-25.87E E down hsa-miR-3hsa-miR-31.46E E down hsa-miR-3hsa-miR-37.05E E down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR-38.2E-058.2E E down hsa-miR-3hsa-miR-31.46E E down

B2 vs C Result systematisystematip (Corr)pFC (abs)RegulatioRegulatioB10:gTotaB11:gTotaB13:gTotaB20:gTotaB22:gTotaB42:gTotaB47:gTotaB5:gTotalB5:gTotal hsa-miR-4hsa-miR up hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR E down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-2hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR E down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR E down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR E down hsa-miR-4hsa-miR down hsa-miR-4hsa-miR down

B3 vs C Result systematisystemati p (Corr)pFC (abs)RegulatioRegulatio TB19:gT o TB3:gTotaTB3:gTota TB35:gT o TB29:gT o TB12:gT o TB17:gT o 1_1:gTot a 1_2:gTot a hsa-miR-1hsa-miR up hsa-miR-4hsa-miR up hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-1hsa-miR down hsa-miR-2hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-3hsa-miR down hsa-miR-4hsa-miR down hsa-miR-4hsa-miR down hsa-miR-4hsa-miR down

B2 vs B1 Result systematisystemati p (Corr ) pFC (abs) Regul atio 2_1:g Tota 2_2:g Tota 2_3:g Tota 2_4:g Tota 2_5:g Tota 2_6:g Tota 2_7:g Tota 2_8:g Tota hsa- miR down hsa- miR up hsa- miR down hsa- miR up

B3 vs B1 systematisystemati p (Corr) pFC (abs) RegulatioRegulatio 2_1:gT ota 2_2:gT ota 2_3:gT ota 2_4:gT ota 2_5:gT ota 2_6:gT ota 2_7:gT ota 2_8:gT ota hsa-miR-1hsa-miR up hsa-miR-1hsa-miR up hsa-miR-1hsa-miR up hsa-miR-1hsa-miR E up hsa-miR-3hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-4hsa-miR down hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-6hsa-miR up

B3 vs B2 systematisystemati p (Corr)pFC (abs) RegulatioRegulatio B10:gTot a B11:gTot a B13:gTo ta B20:gTo ta B22:gTo ta B42:gTo ta B47:gTo ta B5:gTotalB5:gTotal hsa-miR-1hsa-miR up hsa-miR-4hsa-miR up hsa-miR-6hsa-miR up hsa-miR-4hsa-miR down hsa-miR-1hsa-miR up hsa-miR-1hsa-miR up hsa-miR-1hsa-miR up hsa-miR-3hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-4hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up hsa-miR-6hsa-miR up

The common expression of difference miRNA molecules among the B1/C, B2/C, B3/C three groups were 50 Together with B3/B1, B3/B2, B2/B1, the common expression of the difference miRNA molecules is hsa-miR-6090, hsa-miR-451a

The common expression of miRNA molecules, which was obtained by using the appropriate tool software, was hsa-miR-6090, hsa-miR-451a. ht p://bioinfogp.cnb.csic.es/tools/venny/

hsa-miR-6090, hsa-miR-451a molecules in the normal control group, mammary gland hyperplasia, breast lymph node metastasis breastlymphnodemetastasisgroupwereexpressed a miRNAmiRNAB1/CB2/CB3/CB2/B1B3/B1B3/B2 hsa-miR- updown up hsa-miR- up

Results The results indicated that the expression of hsa-miR-6090 was down regulated in the normal control group; The expression of hsa-miR-6090 in mammary gland hyperplasia group was lower than that in breast cancer; The expression of hsa-miR-6090 in breast cancer lymph node metastasis was lower than that in breast cancer. For hsa-miR-451a, the expression of hsa-miR-415a molecules in the other groups increased significantly compared with the normal control group. The expression of hsa-miR-451a in breast cancer tissues was up-regulated, and the expression of hsa-miR-451a in breast cancer lymph node metastasis was higher than that in breast cancer.     

Conclusion  Therefore, we speculate that hsa-miR-451a play an important role in the development breast cancer and hsa-miR-6090 and metastasis of  TheFurther validation work will continue

THANK YOU!